acquired
Stage
1
Investors
About
Adnexus Therapeutics developed Adnectins, a class of biologic therapeutics based on human fibronectin, and advanced biologics and antibody candidates for treatment of disease. The company was founded in 2003 and was acquired by Bristol-Myers Squibb in 2007.
Explore Adnexus Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.